Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Receivables (2016 - 2025)

Editas Medicine (EDIT) has disclosed Receivables for 11 consecutive years, with $8.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 6352.38% to $8.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.1 million, a 6352.38% increase, with the full-year FY2024 number at $16.3 million, up 59.67% from a year prior.
  • Receivables was $8.1 million for Q3 2025 at Editas Medicine, up from $588000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $16.3 million in Q4 2024 to a low of $120000.0 in Q3 2022.
  • A 5-year average of $2.6 million and a median of $588000.0 in 2025 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 95.59% in 2021, then surged 6352.38% in 2025.
  • Editas Medicine's Receivables stood at $267000.0 in 2021, then skyrocketed by 1826.97% to $5.1 million in 2022, then surged by 98.0% to $10.2 million in 2023, then soared by 59.67% to $16.3 million in 2024, then tumbled by 50.02% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Receivables are $8.1 million (Q3 2025), $588000.0 (Q2 2025), and $510000.0 (Q1 2025).